Formosa Laboratories, Inc.

Overview

Formosa Laboratories, Inc. is a pharmaceutical company based in Taiwan, founded in 1995, with 501-1,000 employees.

Active pharmaceutical ingredients supplied

Substances Formosa Laboratories, Inc. is evidenced to supply (US FDA Drug Master File or EU CEP). Open any ingredient to see its full supplier landscape, CAS number and patent status.

API / Drug Master Files

Formosa Laboratories, Inc. holds 53 active (55 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• CAPIVASERTIBActive2026-01-12
• ZAVEGEPANT HYDROCHLORIDEActive2025-11-28
• PITAVASTATIN CALCIUM HYDRATEActive2025-09-30
• ABEMACICLIBActive2025-01-24
• DOTA (Tetraxetan)Active2022-07-22
• GADOBUTROL MONOHYDRATEActive2021-12-30
• FERRIC CARBOXYMALTOSEActive2020-12-31
• ERIBULIN MESYLATEActive2020-11-30
• IMATINIB MESYLATEActive2020-10-20
• ELAGOLIX SODIUMActive2020-06-30
• RUCAPARIB CAMSYLATEActive2019-12-26
• GADOTERATE MEGLUMINEActive2019-09-12
• PATIROMER SORBITEX CALCIUMActive2019-06-06
• CALCIFEDIOLActive2019-05-03
• NINTEDANIB ESYLATEActive2018-04-02

Showing 15 of 55 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Formosa Laboratories, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.